The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first ...

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.

Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...

Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq ...

Recent health news includes India's clarification on a non-current mpox case, a record rise in Summit Therapeutics shares due ...

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

Keytruda+Padcev was approved for treating locally ... Here’s how the eight major stocks performed in the last five trading sessions. Image Source: Zacks Investment Research In the last five ...

Image / Getty Big pharma has spent almost US ... treatments hit the market including AstraZeneca’s Enhertu, Merck’s Keytruda and Novartis’ Pluvicto.